This wiki has undergone a migration to Confluence found Here
Difference between revisions of "BiologicallyDerivedProduct FHIR Resource Proposal"
Jump to navigation
Jump to search
Kirt Schaper (talk | contribs) |
Kirt Schaper (talk | contribs) |
||
| Line 92: | Line 92: | ||
Are there any source specifications that you wish to consult but are concerned about access to or expertise to consider? --> | Are there any source specifications that you wish to consult but are concerned about access to or expertise to consider? --> | ||
| − | + | * Patient undergoes hematopoetic cell transplantation (HCT) using autologous BiologicallyDerivedProduct | |
| − | + | * Patient undergoes HCT using HLA-matched BiologicallyDerivedProduct from another person | |
| − | + | * Patient receives post-HCT infusion of donor t-cells | |
| − | + | * Patient receives blood (BiologicallyDerivedProduct) transfusion | |
| − | Patient undergoes hematopoetic cell transplantation (HCT) using autologous BiologicallyDerivedProduct | + | * Patient receives HLA-matched platelets (BiologicallyDerivedProduct) |
| − | Patient undergoes HCT using HLA-matched BiologicallyDerivedProduct from another person | + | * Patient receives heart transplant |
| − | Patient receives post-HCT infusion of donor t-cells | + | * Patient undergoes cardiac surgery receiving pig heart valve |
| − | Patient receives blood (BiologicallyDerivedProduct) transfusion | ||
| − | Patient receives HLA-matched platelets (BiologicallyDerivedProduct) | ||
| − | Patient receives heart transplant | ||
| − | Patient undergoes cardiac surgery receiving pig heart valve | ||
==Resource Relationships== | ==Resource Relationships== | ||
Revision as of 22:11, 9 September 2017
This page documents a Pending FHIR Resource Proposal
Contents
- 1 BiologicallyDerivedProduct
- 1.1 Owning committee name
- 1.2 Committee Approval Date:
- 1.3 Contributing or Reviewing Work Groups
- 1.4 FHIR Resource Development Project Insight ID
- 1.5 Scope of coverage
- 1.6 RIM scope
- 1.7 Resource appropriateness
- 1.8 Expected implementations
- 1.9 Content sources
- 1.10 Resource Relationships
- 1.11 Timelines
- 1.12 gForge Users
- 1.13 When Resource Proposal Is Complete
- 1.14 FMG Notes
BiologicallyDerivedProduct
Owning committee name
Committee Approval Date:
Please enter the date that the committee approved this Resource proposal
Contributing or Reviewing Work Groups
- Orders and Observations
- Pharmacy
FHIR Resource Development Project Insight ID
Scope of coverage
Substances taken from one biological entity (person, animal, etc) or modifications of such substances, intended to be injected, transplanted or grafted to another (possibly the same) biological entity. This includes but is not limited to:
- blood (whole, extracted cells, plasma, etc)
- hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction)
- organs
- tissues (porcine valves, skin, bovine cardiac tissue, etc.)
- manipulated cells (e.g. CAR T-cells)
RIM scope
Resource appropriateness
Expected implementations
Content sources
- Patient undergoes hematopoetic cell transplantation (HCT) using autologous BiologicallyDerivedProduct
- Patient undergoes HCT using HLA-matched BiologicallyDerivedProduct from another person
- Patient receives post-HCT infusion of donor t-cells
- Patient receives blood (BiologicallyDerivedProduct) transfusion
- Patient receives HLA-matched platelets (BiologicallyDerivedProduct)
- Patient receives heart transplant
- Patient undergoes cardiac surgery receiving pig heart valve
Resource Relationships
Timelines
gForge Users
When Resource Proposal Is Complete
When you have completed your proposal, please send an email to FMGcontact@HL7.org
